CU06-1004 (Sac-1004) is an orally active compound that acts as an endothelial dysfunction blocker. It mitigates endothelial dysfunction by inhibiting hyperpermeability and inflammation. The compound demonstrates efficacy in reducing vascular leakage and inflammation across multiple animal models, including those for diabetic retinopathy, stroke, cancer, and inflammatory bowel disease. Additionally, CU06-1004 improves conditions in a CDAA-induced mouse model of NASH and enhances cardiac function [1] [2] [3].